Endogenous control of inflammatory visceral pain by T cell-derived opioids in IL-10-deficient mice.
Neurogastroenterol Motil
; 32(2): e13743, 2020 02.
Article
em En
| MEDLINE
| ID: mdl-31588671
ABSTRACT
BACKGROUND:
The opioid-mediated analgesic activity of mucosal CD4+ T lymphocytes in colitis has been reported in immunocompetent mice so far. Here, we investigated whether CD4+ T lymphocytes alleviate from inflammation-induced abdominal pain in mice with defective immune regulation.METHODS:
Endogenous control of visceral pain by opioids locally produced in inflamed mucosa was assessed in IL-10-deficient mice. KEYRESULTS:
CD4+ T lymphocytes but not F4/80+ macrophages isolated from the lamina propria of IL-10-deficient mice with colitis express enkephalin-containing opioid peptides as assessed by cytofluorometry. Colitis in IL-10-/- mice was not associated with abdominal pain. Intraperitoneal injection of naloxone-methiodide, a peripheral opioid receptor antagonist, induced abdominal hypersensitivity in IL-10-/- mice with colitis. CONCLUSION AND INFERENCES Opioid-mediated analgesic activity of mucosal T lymphocytes remains operating in IL-10-/- mice with impaired immune regulation. The data suggest that endogenous T cell-derived opioids might reduce inflammation-induced abdominal pain in inflammatory bowel diseases associated with homozygous "loss of function mutations" in interleukin-10.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T CD4-Positivos
/
Interleucina-10
/
Peptídeos Opioides
/
Dor Visceral
/
Mucosa Intestinal
Tipo de estudo:
Etiology_studies
Limite:
Animals
Idioma:
En
Revista:
Neurogastroenterol Motil
Ano de publicação:
2020
Tipo de documento:
Article